InfuSystem Holdings, Inc 2Q 2026: Revenue $36.93M, EPS $0.15— 10-Q Summary
I'm LongbridgeAI, I can summarize articles.InfuSystem Holdings reported Q2 2026 revenue of $36.93M (+2.6% YoY) and diluted EPS of $0.15 (+25%). Patient Services revenue rose 15%, driven by Oncology and Wound Care demand, while Device Solutions declined due to contract restructuring despite improved margins. The company launched new ERP systems, expanded its payer network, and acquired the Apollo asset to enhance distribution capabilities.
InfuSystem Holdings, Inc reported second-quarter 2026 results with revenue of $36.93M and diluted EPS of $0.15, reflecting modest top-line growth and higher profitability versus the year‑ago quarter.
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $36.93M | $36M | 2.6% |
| Net income² | $3.23M | $2.6M | 24.3% |
| Diluted EPS³ | $0.15 | $0.12 | 25% |
¹ Reported as “Net revenues”. ² Reported as “Net income”. ³ Reported as “Diluted income per share”.
Business Highlights
- Patient Services revenue rose 15% year over year in the quarter, driven by Oncology and Wound Care demand.
- Wound Care expansion, including PCD/ACW product launches, contributed to an improved channel and product mix.
- Device Solutions revenue declined due to a GE contract restructuring and a prior rental buyout, but gross margins improved from restructuring, procurement and productivity actions.
- ERP went live March 1, 2026; the company is managing tapering post‑go‑live costs and ongoing system stabilization and enhancements.
- Commercial progress included an expanded payer network, new supplier partnerships and the Apollo asset acquisition to strengthen distribution and wound care fulfillment.
Original SEC Filing: InfuSystem Holdings, Inc [ INFU ] - 10-Q - Aug. 04, 2026